Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).

Insulin dose and number of prandial insulin injections In the Type 1 diabetes group, the daily doses of total, basal and prandial insulins decreased significantly at both 6 and 12 months irrespective of previous basal insulins, except for prandial insulin in the NPH group at 6 months, where there was a decrease that did not reach statistical significance (Fig. 3 a).

also in 111,027 other papers